Video

High Cost Impacts PCSK9 Inhibitor Access

Author(s):

Lauren Santye, Assistant Editor

Mark Tesell, PharmD, BCPS, discusses how the high cost of PCSK9 inhibitors effected uptake of the cholesterol-lowering drug.

Mark Tesell, PharmD, BCPS, discusses how the high cost of PCSK9 inhibitors effected uptake of the cholesterol-lowering drug.

Newsletter

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.

Subscribe Now!
Related Videos
Pharmacist and doctor -- Image credit: ake1150 | stock.adobe.com
Related Content
FDA logo on smartphone -- Image credit: gguy | stock.adobe.com
August 19th 2025

FDA Issues CRL to Vatiquinone NDA Indicated For Friedreich Ataxia

Gillian McGovern, Associate Editor
Pharmacy Focus: Integrating SBIRT in Pharmacies to Combat Substance Use Disorder
August 19th 2025

Pharmacy Focus: Integrating SBIRT in Pharmacies to Combat Substance Use Disorder

Luke Halpern, Assistant Editor
Bleeding stroke brain artery, Cellular structure with intricate connections and a vibrant red nucleus, representing biological elements.
August 19th 2025

Atorvastatin Improves Outcomes, LDL-C Following Pipeline Therapy for Intracranial Aneurysms

Luke Halpern, Assistant Editor
Pharmacy Focus: Pharmacists' Role in Medical Cannabis Counseling and Patient Education
August 19th 2025

Pharmacy Focus: Pharmacists' Role in Medical Cannabis Counseling and Patient Education

Luke Halpern, Assistant Editor Jill Simonian, PharmD Codi Peterson, PharmD, MS
Sunvozertinib Brings Changes in Non-Small Cell Lung Cancer Treatment
August 19th 2025

Sunvozertinib Brings Changes in Non-Small Cell Lung Cancer Treatment

Amy C. Nieto, BS, PharmD Candidate
Dynamic 3D Visualization of Cholesterol Lowering Process in Bloodstream
August 19th 2025

Lipid-Lowering Effects Discovered in FDA-Approved Drugs Using Machine Learning

Luke Halpern, Assistant Editor